

Hareth Nahi, publication list:

1. EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions. Alzrigat M, Atienza Párraga A, Agarwal A, Zureigat H, Österborg A, **Nahi H**, Ma A, Jin J, Nilsson K, Öberg F, Kalushkova A, Jernberg-Wiklund H. **Oncotarget**, 2017. PMID: 28052011
1. Daratumumab, Lenalidomide and Dexamethasone for Relapsed/Refractory Myeloma. Dimopoulos MA, Oriol A, **Nahi H**, San Miguel J, Bahlis NJ, Usmani SZ, Rabin N, Orłowski RZ, Komarnicki M, Plesner T, Yoon SS, Yehuda DB, Richardson PG, Goldschmidt H, Donna Reece D, Steen Lisby S, Khokhar NK, O'Rourke L, Chiu C, Xiang Qin X, Guckert M, Ahmadi T, Moreau P, **N Engl J Med**. 2016. PMID: 27705267.
2. Jurczynski A, **Nahi H**, Avivi I, Gozzetti A, Niesvizky R, Yadlapati S, Jayabalan D, Robak P, Pika T, Andersen K, Rasche L, Mądry K, Woszczyk D, Rażny M, Usnarska-Zubkiewicz L, Knopińska-Posłuszny W, Wojciechowska M, Guzik-Kazimierzka R, Joks M, Grosicki S, Ciepluch H, Rymko M, Vesole D. Characteristics and outcomes of patients with multiple myeloma age 21-40 years versus 41-60 years: a multi-institutional case-control study. **Br J Haematol**. 2016. PMID: 27682187.
3. Rosengren S, Mellqvist UH, **Nahi H**, Forsberg K, Lenhoff S, Strömberg O, Ahlberg L, Linder O, and Carlson K. Outcome of AL amyloidosis after high dose Melphalan and autologous stem cell transplantation in Sweden, long term results from all patients treated in 1994-2009." **Bone Marrow Transplant**. 2016. PMID: 27694943
4. **Nahi H**, Afram G, Liwing J, Heeg B, Mattsson J, Katarina LB, Björkstrand B, Gahrton G, and Ljungman P. Treosulfan Plus Fludarabine – Encouraging Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation in Multiple Myeloma. Accepted at **Journal of Cancer Science and Clinical Oncology**, May 2016. ISSN: 2394-6520.
5. Mitchell JS, Ni Li N, Weinhold N, Försti A, Ali M, van Duin M, Thorleifsson G, Johnson DC, Chen B Halvarsson BM, Gudbjartsson DF, Kuiper R, Stephens OW, Bertsch U, Broderick P, Campo C, Einsele H, Gregory WA, Gullberg U, Henrion M, Hillengass J, Hoffmann P, Jackson GH, Johnsson E, Jöud M, Kristinsson S, Lenhoff S, Lenive O, Mellqvist UH, Migliorini G, **Nahi H**, Nelander S, Nickel J, Rafnar T, Ross FM, Silva Filho MI, Swaminathan B, Turesson I, Vangsted A, Vogel U, Waage A, Walker BA, Wihlborg AK, Broyl A, Davies FE, Thorsteinsdottir N, Langer C, Hansson M, Kaiser M, Sonneveld P, Stefansson K, Morgan G, Goldschmidt H, Hemminki K, Nilsson B, Houlston R. Genome-wide association study identifies multiple susceptibility loci for multiple myeloma. **Nature Communications**, 2016, PMID: 273636.
6. Usmani S, Weiss BM, Plesner T, Bahlis N, Belch A, Lonial S, Lokhorst HM, Voorhees PM, Richardson PG, Chari A, Sasser K, Axel A, Feng H, Uhlir CM, Wang J, Khan I, Ahmadi T, **Nahi H**. Clinical Efficacy of Daratumumab Monotherapy in Patients With Heavily Pretreated Relapsed or Refractory Multiple Myeloma. **Blood** 2016 May. PMID: 27216216.
7. Borg S, **Nahi H**, Hansson M, Lee D, Elvidge J, Persson U. Cost effectiveness of pomalidomide in patients with relapsed and refractory multiple myeloma in Sweden. **Acta Oncol**. 2016. PubMed PMID: 27123742.

8. Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, Sandhu I, Ganly P, Baker BW, Jackson SR, Stoppa AM, Simpson DR, Gimsing P, Palumbo A, Garderet L, Cavo M, Kumar S, Touzeau C, Buadi FK, Laubach JP, Berg DT, Lin J, Di Bacco A, Hui AM, van de Velde H, Richardson PG; TOURMALINE-MM1 Study Group. Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. **N Engl J Med.** 2016 Apr. PubMed PMID: 27119237.
9. Moreau P, van de Donk NW, Miguel JS, Lokhorst H, **Nahi H**, Ben-Yehuda D, Cavo M, Cook G, Delforge M, Einsele H, Zweegman S, Ludwig H, Driessen C, Palumbo A, Facon T, Plesner T, Dimopoulos M, Sondergeld P, Sonneveld P, Mateos MV. Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma. **Drugs.** 2016 Apr 25. PubMed PMID: 27113582.
10. urczynszyn A, Grzasko N, Gozzetti A, Czepiel J, Cerase A, Hungria V, Crusoe E, Silva Diaz AL, Vij R, Fiala MA, Caers J, Rasche L, Nooka AK, Lonial S, Vesole DH, Philip S, Gangatharan S, Druzd-Sitek A, Walewski J, Corso A, Cocito F, Vekemans MM, Atilla E, Beksac M, Leleu X, Davila J, Badros A, Aneja E, Abildgaard N, Kastritis E, Fantl D, Schutz N, Pika T, Butrym A, Olszewska-Szopa M, Usnarska-Zubkiewicz L, Usmani S, **Nahi H**, Chim CS, Shustik C, Madry K, Lentzsch S, Swiderska A, Helbig G, Guzicka-Kazimierczak R, Lendvai N, Waage A, Andersen KT, Murakami H, Zweegman S, Castillo JJ. Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice. **Am J Hematol.** 2016 Mar 8. PubMed PMID: 26955792.
11. **Nahi H**, Våtsveen TK, Lund J, Heeg BM, Preiss B, Alici E, Møller MB, Wader KF, Møller HE, Grøseth LA, Østergaard B, Dai HY, Holmberg E, Gahrton G, Waage A, Abildgaard N. Proteasome inhibitors and IMiDs can overcome some high-risk cytogenetics in multiple myeloma but not gain 1q21. **Eur J Haematol.** 2016 Jan; PMID: 25779478.
12. Giralt S, Garderet L, Durie B, Cook G, Gahrton G, Bruno B, Hari P, Lokhorst H, McCarthy P, Krishnan A, Sonneveld P, Goldschmidt H, Jagannath S, Barlogie B, Mateos M, Gimsing P, Sezer O, Mikhael J, Lu J, Dimopoulos M, Mazumder A, Palumbo A, Abonour R, Anderson K, Attal M, Blade J, Bird J, Cavo M, Comenzo R, de la Rubia J, Einsele H, Garcia-Sanz R, Hillengass J, Holstein S, Johnsen HE, Joshua D, Koehne G, Kumar S, Kyle R, Leleu X, Lonial S, Ludwig H, **Nahi H**, Nooka A, Orłowski R, Rajkumar V, Reiman A, Richardson P, Riva E, San Miguel J, Tureson I, Usmani S, Vesole D, Bensinger W, Qazilbash M, Efebera Y, Mohty M, Gasparreto C, Gajewski J, LeMaistre CF, Bredeson C, Moreau P, Pasquini M, Kroeger N, Stadtmauer E. American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. **Biol Blood Marrow Transplant.** 2015 Dec; PMID: 26428082;
13. Alici E, Chrobok M, Lund J, Ahmadi T, Khan I, Duru AD, **Nahi H**. Re-challenging with anti-CD38 monotherapy in triple-refractory multiple myeloma patients is a feasible and safe approach. **Br J Haematol.** 2015 Oct 12. PubMed PMID: 26455823.
14. Lokhorst HM, Plesner T, Laubach JP, **Nahi H**, Gimsing P, Hansson M, Minnema MC, Lassen U, Krejcik J, Palumbo A, van de Donk NW, Ahmadi

- T, Khan I, Uhlar CM, Wang J, Sasser AK, Losic N, Lisby S, Basse L, Brun N, Richardson PG. Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. **N Engl J Med**. 2015 Sep, PubMed PMID: 26308596.
15. Body JJ, Pereira J, Sleeboom H, Maniadas N, Terpos E, Acklin YP, Finek J, Gunther O, Hechmati G, Mossman T, Costa L, Rogowski W, **Nahi H**, von Moos R. Health resource utilization associated with skeletal-related events: results from a retrospective European study. **Eur J Health Econ**. 2015 Aug 8. PMID: 26253584.
  16. Hansson M, Gimsing P, Badros A, Niskanen TM, **Nahi H**, Offner F, Salomo M, Sonesson E, Mau-Sorensen M, Stenberg Y, Sundberg A, Teige I, Van Droogenbroeck J, Wichert S, Zangari M, Frendeus B, Korsgren M, Poelman M, Tricot G. A Phase I Dose-Escalation Study of Antibody BI-505 in Relapsed/Refractory Multiple Myeloma. **Clin Cancer Res**. 2015 Jun. PubMed PMID: 25712687.
  17. Grövdal M, **Nahi H**, Gahrton G, Liwing J, Waage A, Abildgaard N, Pedersen PT, Hammerström J, Laaksonen A, Bazia P, Terava V, Ollikainen H, Silvennoinen R, Putkonen M, Anttila P, Porkka K, Remes K. Autologous stem cell transplantation versus novel drugs or conventional chemotherapy for patients with relapsed multiple myeloma after previous ASCT. **Bone Marrow Transplant**. 2015. PMID: 25867654.
  18. Swaminathan B, Thorleifsson G, Jöud M, Ali M, Johnsson E, Ajore R, Sulem P, Halvarsson BM, Eyjolfsson G, Haraldsdottir V, Hultman C, Ingelsson E, Kristinsson SY, Kähler AK, Lenhoff S, Masson G, Mellqvist UH, Månsson R, Nelander S, Olafsson I, Sigurðardottir O, Steingrimsdóttir H, Vangsted A, Vogel U, Waage A, **Nahi H**, Gudbjartsson DF, Rafnar T, Turesson I, Gullberg U, Stefánsson K, Hansson M, Thorsteinsdóttir U, Nilsson B. Variants in ELL2 influencing immunoglobulin levels associate with multiple myeloma. **Nat Commun**. 2015 May. PMID: 26007630.
  19. Falk IJ, Willander K, Chaireti R, Lund J, **Nahi H**, Hermanson M, Gréen H, Lotfi K, Söderkvist P. TP53 mutations and MDM2(SNP309) identify subgroups of AML patients with impaired outcome. **Eur J Haematol**. 2015 Apr; PMID: 25156865.
  20. Hellman U, Lundgren HE, Westermark P, Stafberg C, **Nahi H**, Tachlinski S, Guggi M, Flogegård M, Hamid M, Escher SA, Suhr OB. A genealogical and clinical study of the phenotypical variation within the Swedish transthyretin His88Arg (p. His108Arg) amyloidosis family. **Eur J Med Genet**. 2015 Apr; PMID: 25721874.
  21. Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Špička I, Oriol A, Hájek R, Rosiñol L, Siegel DS, Mihaylov GG, Goranova-Marinova V, Rajnics P, Suvorov A, Niesvizky R, Jakubowiak AJ, San-Miguel JF, Ludwig H, Wang M, Maisnar V, Minarik J, Bensinger WI, Mateos MV, Ben-Yehuda D, Kukreti V, Zojwalla N, Tonda ME, Yang X, Xing B, Moreau P, Palumbo A; ASPIRE Investigators. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. **N Engl J Med**. 2015 Jan. PMID: 25482145.
  22. Duru AD, Sutlu T, Wallblom A, Uttervall K, Lund J, Stellan B, Gahrton G, **Nahi H**, Alici E. Deletion of Chromosomal Region 8p21 Confers Resistance to Bortezomib and Is Associated with Upregulated Decoy TRAIL Receptor Expression in Patients with Multiple Myeloma. **PLoS One**. 2015 Sep 17;10(9):e0138248. doi: PMID: 26378933.
  23. Jakobsen Falk I, Fyrberg A, Paul E, **Nahi H**, Hermanson M, Rosenquist R, Höglund M, Palmqvist L, Stockelberg D, Wei Y, Gréen H, Lotfi K. Impact of

- ABCB1 single nucleotide polymorphisms 1236C>T and 2677G>T on overall survival in FLT3 wild-type de novo AML patients with normal karyotype. **Br J Haematol.** 2014 Dec; PMID: 25155901.
24. Heeg B, Van Agthoven M, van Beurden-Tan C, Liwing J, Mellqvist UH, Plesner T, Logman F, Aschan J, Einsele H, Treur M, Barendse M, Richardson PG, Palumbo A, **Nahi H**, Sonneveld P. Treatment Sequencing Survival Model for Patients with Multiple Myeloma Ineligible for Stem Cell Transplantation (SCT). **Value Health.** 2014 Nov; PMID: 27202167.
  25. Thilakarathne P, Diels J, van Sanden S, Liwing J, Chirita O, Van Agthoven M, **Nahi H**. Bortezomib Re-treatment in Patients with Multiple Myeloma (MM). A Real World Medical Practice Experience from a Swedish National Registry. **Value Health.** 2014 Nov; PMID: 27202162.
  26. Thilakarathne P, Diels J, van Sanden S, Liwing J, Van Agthoven M, Chirita O, **Nahi H**. Comparative Real World Effectiveness of Novel Agents Versus Conventional Therapies in Multiple Myeloma Patients in Sweden. **Value Health.** 2014 Nov; PMID: 27201764.
  27. San-Miguel JF, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Günther A, Nakorn TN, Siritanaratkul N, Corradini P, Chuncharunee S, Lee JJ, Schlossman RL, Shelekhova T, Yong K, Tan D, Numbenjapon T, Cavenagh JD, Hou J, LeBlanc R, **Nahi H**, Qiu L, Salwender H, Pulini S, Moreau P, Warzocha K, White D, Bladé J, Chen W, de la Rubia J, Gimsing P, Lonial S, Kaufman JL, Ocio EM, Veskovski L, Sohn SK, Wang MC, Lee JH, Einsele H, Sopala M, Corrado C, Bengoudifa BR, Binlich F, Richardson PG. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. **Lancet Oncol.** 2014 Oct; PMID: 25242045.
  28. Benboubker L, Dimopoulos MA, Dispenzieri A, Catalano J, Belch AR, Cavo M, Pinto A, Weisel K, Ludwig H, Bahlis N, Banos A, Tiab M, Delforge M, Cavenagh J, Geraldès C, Lee JJ, Chen C, Oriol A, de la Rubia J, Qiu L, White DJ, Binder D, Anderson K, Feraud JP, Moreau P, Attal M, Knight R, Chen G, Van Oostendorp J, Jacques C, Ervin-Haynes A, Avet-Loiseau H, Hulin C, Facon T; FIRST Trial Team. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. **N Engl J Med.** 2014 Sep PMID: 25184863.
  29. Ludwig H, Sonneveld P, Davies F, Bladé J, Boccadoro M, Cavo M, Morgan G, de la Rubia J, Delforge M, Dimopoulos M, Einsele H, Facon T, Goldschmidt H, Moreau P, **Nahi H**, Plesner T, San-Miguel J, Hajek R, Sondergeld P, Palumbo A. European perspective on multiple myeloma treatment strategies in 2014. **Oncologist.** 2014 Aug; PMID: 25063227.
  30. Liwing J, Uttervall K, Lund J, Aldrin A, Blimark C, Carlson K, Enestig J, Flogegård M, Forsberg K, Gruber A, Haglöf K, Viele H, Johansson P, Lauri B, Mellqvist UH, Swedin A, Svensson M, Näsman P, Alici E, Gahrton G, Aschan J, **Nahi H**. Improved survival in myeloma patients: starting to close in on the gap between elderly patients and a matched normal population. **Br J Haematol.** 2014. PMID:24313224.
  31. Chng WJ, Dispenzieri A, Chim CS, Fonseca R, Goldschmidt H, Lentzsch S, Munshi N, Palumbo A, Miguel JS, Sonneveld P, Cavo M, Usmani S, Durie BG, Avet-Loiseau H; International Myeloma Working Group. IMWG

- consensus on risk stratification in multiple myeloma. **Leukemia**. 2014 Feb; PubMed PMID: 23974982.
32. **Nahi H**, Svedmyr E, Lerner R. Bendamustine in combination with high-dose radiotherapy and thalidomide is effective in treatment of multiple myeloma with central nervous system involvement. **Eur J Haematol**. 2014; PubMed PMID: 24330308.
  33. Lund J, Uttervall K, Liwing J, Gahrton G, Alici E, Aschan J, Holmberg E, **Nahi H**. **Addition** of thalidomide to melphalan and prednisone treatment prolongs survival in multiple myeloma--a retrospective population based study of 1162 patients. **Eur J Haematol**. 2014 Jan; PubMed PMID: 24118547.
  34. Uttervall K, Duru AD, Lund J, Liwing J, Gahrton G, Holmberg E, Aschan J, Alici E, **Nahi H**. The use of novel drugs can effectively improve response, delay relapse and enhance overall survival in multiple myeloma patients with renal impairment. **PLoS One**. 2014 Jul; PMID: 25003848.
  35. Falk IJ, Fyrberg A, Paul E, Nahi H, Hermanson M, Rosenquist R, Höglund M, Palmqvist L, Stockelberg D, Wei Y, Gréen H, Lotfi K. Decreased survival in normal karyotype AML with single-nucleotide polymorphisms in genes encoding the AraC metabolizing enzymes cytidine deaminase and 5'-nucleotidase. **Am J Hematol**. 2013 Dec; PMID: 23873772.
  36. Mellqvist UH, Gimsing P, Hjertner O, Lenhoff S, Laane E, Remes K, Steingrimsdottir H, Abildgaard N, Ahlberg L, Blimark C, Dahl IM, Forsberg K, Gedde-Dahl T, Gregersen H, Gruber A, Guldbrandsen N, Haukås E, Carlson K, Kvam AK, **Nahi H**, Lindås R, Andersen NF, Turesson I, Waage A, Westin J; Nordic Myeloma Study Group. Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial. **Blood**. 2013 Jun; PMID: 23616624.
  37. Fernández de Larrea C, Kyle RA, Durie BG, Ludwig H, Usmani S, Vesole DH, Hajek R, San Miguel JF, Sezer O, Sonneveld P, Kumar SK, Mahindra A, Comenzo R, Palumbo A, Mazumber A, Anderson KC, Richardson PG, Badros AZ, Caers J, Cavo M, LeLeu X, Dimopoulos MA, Chim CS, Schots R, Noeul A, Fantl D, Mellqvist UH, Landgren O, Chanan-Khan A, Moreau P, Fonseca R, Merlini G, Lahuerta JJ, Bladé J, Orłowski RZ, Shah JJ; International Myeloma Working Group. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. **Leukemia**. 2013 Apr; PMID: 23288300.
  38. Uttervall K, Admasie J, Alici E, Lund J, Liwing J, Aschan J, Barendse M, Deneberg S, Mellqvist UH, Carlson K, **Nahi H**. A combination regimen of bortezomib, cyclophosphamide and betamethasone gives quicker, better and more durable response than VAD/CyBet regimens: results from a Swedish retrospective analysis. *Acta Haematol*. 2013; PMID: 23363691.
  39. Sutlu T, Alici E, Gahrton G, **Nahi H**. In search of the molecular consequences of 8p21 deletion in multiple myeloma: commentary on Gmidéne et al. **Med Oncol**. 2013; PMID: 23568164.
  40. **Nahi H**, Remberger M, Machaczka M, Ungerstedt J, Mattson J, Ringden O, Le-Blanc K, Ljungman P, Hägglund H. Different impact of intermediate and unfavourable cytogenetics at the time of diagnosis on outcome of de novo AML after allo-SCT: a long-term retrospective analysis from a single institution. **Med Oncol**. 2012 Dec; PMID: 22234457.

41. Ungerstedt JS, Watz E, Uttervall K, Johansson BM, Wahlin BE, Näsman P, Ljungman P, Gruber A, Axdorph Nygell U, **Nahi H**. Autologous hematopoietic stem cell transplantation in multiple myeloma and lymphoma: an analysis of factors influencing stem cell collection and hematological recovery. **Med Oncol**. 2012 Sep; PMID: 21779930.
42. Hjorth M, Hjertner Ø, Knudsen LM, Gulbrandsen N, Holmberg E, Pedersen PT, Andersen NF, Andréasson B, Billström R, Carlson K, Carlsson MS, Flogegård M, Forsberg K, Gimsing P, Karlsson T, Linder O, **Nahi H**, Othzén A, Swedin A; Nordic Myeloma Study Group (NMSG). Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study. **Eur J Haematol**. 2012 Jun, PMID: 22404182.
43. Machaczka M, **Nahi H**, Karbach H, Klimkowska M, Hägglund H. Successful treatment of recurrent malignancy-associated hemophagocytic lymphohistiocytosis with a modified HLH-94 immunochemotherapy and allogeneic stem cell transplantation. **Med Oncol**. 2012 Jun; PMID: 21533602.
44. Gréen H, Falk IJ, Lotfi K, Paul E, Hermansson M, Rosenquist R, Paul C, **Nahi H**. Association of ABCB1 polymorphisms with survival and in vitro cytotoxicity in de novo acute myeloid leukemia with normal karyotype. **Pharmacogenomics J**. 2012 Apr; PMID: 20938465.
45. Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J, Haessler J, Feather J, Hoering A, Moreau P, LeLeu X, Hulin C, Klein SK, Sonneveld P, Siegel D, Bladé J, Goldschmidt H, Jagannath S, Miguel JS, Orłowski R, Palumbo A, Sezer O, Rajkumar SV, Durie BG; International Myeloma Working Group. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. *Leukemia*. 2012 Jan;26(1):149-57. doi: 10.1038/leu.2011.196. Epub 2011 Jul 29. Erratum in: **Leukemia**. 2012 May;26(5):1153. Nari, Hareth [corrected to **Nahi, Hareth**]. PMID: 21799510.
46. Deneberg S, Guardiola P, Lennartsson A, Qu Y, Gaidzik V, Blanchet O, Karimi M, Bengtzén S, **Nahi H**, Uggla B, Tidefelt U, Höglund M, Paul C, Ekwall K, Döhner K, Lehmann S. Prognostic DNA methylation patterns in cytogenetically normal acute myeloid leukemia are predefined by stem cell chromatin marks. **Blood**. 2011 Nov, PMID: 21960591.
47. Machaczka M, Vaknäs J, Klimkowska M, Nahi H, Hägglund H. Acquired hemophagocytic lymphohistiocytosis associated with multiple myeloma. **Med Oncol**. 2011 Jun; PMID: 20358309.
48. Richardson GE, Ciuleanu TE, Costa L, Gans SJ, Garcia Saenz JÁ, Hirsh V, Hungria V, Krzakowski M, Manegold C, **Nahi H**, Novello S, Petzer AL, Rader ME, Solal-Celigny P, Vadhan-Raj S, Vansteenkiste JF, Woll PJ, Ke C, Chung K, Yeh H. Denosumab versus zoledronic acid in patients with bone metastases from solid tumors other than breast and prostate cancers or multiple myeloma: A number needed to treat (NNT) analysis. **J Clin Oncol**. 2011 May. PMID: 28021780
49. Ali D, Jönsson-Videsäter K, Deneberg S, Bengtzén S, **Nahi H**, Paul C, Lehmann S. APR-246 exhibits anti-leukemic activity and synergism with conventional chemotherapeutic drugs in acute myeloid leukemia cells. **Eur J Haematol**. 2011 Mar; PMID: 21114538.

50. **Nahi H**, Sutlu T, Jansson M, Alici E, Gahrton G. Clinical impact of chromosomal aberrations in multiple myeloma. **J Intern Med.** 2011 Feb; PMID: 21158983.
51. Ludwig H, Beksac M, Bladé J, Cavenagh J, Cavo M, Delforge M, Dimopoulos M, Drach J, Einsele H, Facon T, Goldschmidt H, Harousseau JL, Hess U, Kropff M, Leal da Costa F, Louw V, Magen-Nativ H, Mendeleeva L, **Nahi H**, Plesner T, San-Miguel J, Sonneveld P, Udvardy M, Sondergeld P, Palumbo A. Multiple myeloma treatment strategies with novel agents in 2011: a European perspective. **Oncologist.** 2011; PMID: 21441574.
52. Sutlu T, Stellan B, Gilljam M, Quezada HC, **Nahi H**, Gahrton G, Alici E. Clinical-grade, large-scale, feeder-free expansion of highly active human natural killer cells for adoptive immunotherapy using an automated bioreactor. **Cytotherapy.** 2010 Dec; PMID: 20795758.
53. Gahrton C, **Nahi H**, Jansson M, Wallblom A, Alici E, Sutlu T, Samuelsson J, Gahrton G. Constitutional inv(3) in myelodysplastic syndromes. **Leuk Res.** 2010 Dec, PMID: 20542563.
54. Deneberg S, Grövdal M, Karimi M, Jansson M, Nahi H, Corbacioglu A, Gaidzik V, Döhner K, Paul C, Ekström TJ, Hellström-Lindberg E, Lehmann S. Gene-specific and global methylation patterns predict outcome in patients with acute myeloid leukemia. **Leukemia,** 2010 May; PMID: 20237504.
55. Paul E, Uggla B, Deneberg S, Bengtzen S, Hermansson M, Dahlman I, Rosenquist R, Wiman KG, **Nahi H**. Low p14ARF expression in de novo acute myeloid leukemia with normal karyotype is associated with poor survival. **Leuk Lymphoma.** 2009 Sep; PMID: 19626541.
56. Paul E, Sutlu T, Deneberg S, Alici E, Björkstrand B, Jansson M, Lerner R, Wallblom A, Gahrton G, Nahi H. Impact of chromosome 13 deletion and plasma cell load on long-term survival of patients with multiple myeloma undergoing autologous transplantation. **Oncol Rep.** 2009 Jul; PMID: 19513515.
57. Sutlu T, Alici E, Jansson M, Wallblom A, Dilber MS, Gahrton G, **Nahi H**. The prognostic significance of 8p21 deletion in multiple myeloma. **Br J Haematol.** 2009 Jan;: 19016723.
58. **Nahi H**, Jansson M, Sander B, Ljungman P, Hägglund H. Transmission of chronic lymphocytic leukaemia from a blood stem cell sibling donor to the recipient. **Br J Haematol.** 2008 Dec; PMID: 19036021.
59. **Nahi H**, Hägglund H, Ahlgren T, Bernell P, Hardling M, Karlsson K, Lazarevic VLj, Linderholm M, Smedmyr B, Aström M, Hallböök H. An investigation into whether deletions in 9p reflect prognosis in adult precursor B-cell acute lymphoblastic leukemia: a multi-center study of 381 patients. **Haematologica.** 2008 Nov; PMID: 18728022.
60. Möllgård L, Deneberg S, **Nahi H**, Bengtzen S, Jonsson-Videsäter K, Fioretos T, Andersson A, Paul C, Lehmann S. The FLT3 inhibitor PKC412 in combination with cytostatic drugs in vitro in acute myeloid leukemia. **Cancer Chemother Pharmacol.** 2008 Aug; PMID: 17960382.
61. **Nahi H**, Selivanova G, Lehmann S, Möllgård L, Bengtzen S, Concha H, Svensson A, Wiman KG, Merup M, Paul C. Mutated and non-mutated TP53 as targets in the treatment of leukaemia. **Br J Haematol.** 2008 May; PMID: 18341636.
62. Alici E, Sutlu T, Björkstrand B, Gilljam M, Stellan B, **Nahi H**, Quezada HC, Gahrton G, Ljunggren HG, Dilber MS. Autologous antitumor activity by NK

- cells expanded from myeloma patients using GMP-compliant components. **Blood**. 2008 Mar; PMID: 18192509.
63. **Nahi H**, Lehmann S, Bengtzen S, Jansson M, Möllgård L, Paul C, Merup M. Chromosomal aberrations in 17p predict in vitro drug resistance and short overall survival in acute myeloid leukemia. **Leuk Lymphoma**. 2008 Mar; PMID: 18297528.
  64. Uggla B, Tina E, **Nahi H**, Paul C, Höglund M, Sirsjö A, Tidefelt U. Topoisomerase IIalpha mRNA and protein expression vs. in vitro drug resistance and clinical outcome in acute leukaemia. *Int J Oncol*. 2007 Jul; PMID: 17549416.
  65. Merup M, Lazarevic V, **Nahi H**, Andreasson B, Malm C, Nilsson L, Brune M, LeBlanc K, Kutti J, Birgegård G; Swedish Group for Myeloproliferative Disorders. Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced-intensity conditioning regimens. **Br J Haematol**. 2006 Nov; PMID: 16972981.
  66. **Nahi H**, Merup M, Lehmann S, Bengtzen S, Möllgård L, Selivanova G, Wiman KG, Paul C. PRIMA-1 induces apoptosis in acute myeloid leukaemia cells with p53 gene deletion. **Br J Haematol**. 2006 Jan; PMID: 16398657.
  67. Ljungman P, **Nahi H**, Linde A. Vaccination of patients with haematological malignancies with one or two doses of influenza vaccine: a randomised study. *Br J Haematol*. 2005 Jul; PMID: 15982350.
  68. **Nahi H**, Lehmann S, Mollgard L, Bengtzen S, Selivanova G, Wiman KG, Paul C, Merup M. Effects of PRIMA-1 on chronic lymphocytic leukaemia cells with and without hemizygous p53 deletion. **Br J Haematol**. 2004 Nov; PMID: 15491287.